Skip to main content

Diagnosing and Managing Pediatric Functional Constipation

Sponsored by AbbVie Medical Affairs and Ironwood Pharmaceuticals Intended for Physicians

Chapter 1

Chapter 2

Chapter 3

Chapter 4

Chapter 5

INDICATIONS AND USAGE
Linaclotide is indicated for the treatment of:

  • Irritable bowel syndrome with constipation (IBS-C) in adults
  • Chronic idiopathic constipation (CIC) in adults
  • Functional constipation (FC) in pediatric patients 6 to 17 years of age

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE
Linaclotide is contraindicated in patients less than 2 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.

Chapters

Currently Playing

Coming up next in 0:00

Watched

Placeholder

Chapter 1  |  12m 18s

Currently Playing

Coming up next in 01:05

Watched

Placeholder

Chapter 2  |  17m 10s

Currently Playing

Coming up next in 00:00

Watched

Placeholder

Chapter 3  |  14m 10s

Currently Playing

Coming up next in 00:00

Watched

Placeholder

Chapter 4  |  12m 34s

Currently Playing

Coming up next in 00:00

Watched

Placeholder

Chapter 5  |  31m 43s

Program Objectives

Discuss strategies to improve diagnosis of pediatric functional constipation (FC).

Review current and emerging treatments for pediatric FC.

Explore patient-centered management for pediatric FC.

Dr Chumpitazi

Bruno Chumpitazi, MD

Duke University
School of Medicine

Dr Khlevner

Julie Khlevner, MD

Columbia University
Irving Medical Center

Sharon Perry

Sharon Perry, CNP

University Hospitals – Rainbow
Babies and Children’s Hospital